The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The inspection concluded with one minor observation in Form 483
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
Subscribe To Our Newsletter & Stay Updated